BioNexus Gene Lab Corp.
NasdaqCM:BGLC Lagerbericht
Marktkapitalisierung: US$6.3m
BioNexus Gene Lab Management
Management Kriterienprüfungen 1/4 Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Lee Tan
Geschäftsführender
Prozentsatz des Geschäftsführergehalts n/a Amtszeit als Geschäftsführer less than a year Eigentum des Geschäftsführers n/a Durchschnittliche Amtszeit des Managements keine Daten Durchschnittliche Amtszeit der Vorstandsmitglieder less than a year
Jüngste Management Updates
Bionexus Gene Lab Corp. Announces Resignation of Wei Foong Lim and Koon Wai Wong as Members of the Board of Directors and Member of the Audit Committee, and A Member of the Corporate Governance and Nominating Committee Oct 18 BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024 Sep 10
High number of new and inexperienced directors Jun 28
High number of new and inexperienced directors Feb 14
High number of new and inexperienced directors Nov 14 BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive Officer
Alle Updates anzeigen
BioNexus Gene Lab Submits Formal Request for Hearing Before Nasdaq Hearings Panel to Appeal the Delisting Determination Nov 09
Bionexus Gene Lab Corp. Announces Resignation of Wei Foong Lim and Koon Wai Wong as Members of the Board of Directors and Member of the Audit Committee, and A Member of the Corporate Governance and Nominating Committee Oct 18 BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024 Sep 10
Second quarter 2024 earnings released: US$0.005 loss per share (vs US$0.018 loss in 2Q 2023) Aug 16
High number of new and inexperienced directors Jun 28
The Nasdaq Stock Market Determines BioNexus Gene Lab Eligible for an Additional 180 Calendar Day Extension Period or Until November 4, 2024 to Regain Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2) May 10 BioNexus Gene Lab Corp. announced delayed annual 10-K filing Mar 29
BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stocks Shoot Up 234% But Its P/S Still Looks Reasonable Feb 14
High number of new and inexperienced directors Feb 14 Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab Corp Jan 17
BioNexus Gene Lab Corp. announced delayed 10-Q filing Nov 15
BioNexus Gene Lab Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2) Nov 14
High number of new and inexperienced directors Nov 14 BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive Officer BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Chief Executive Officer
BioNexus Gene Lab Corp. Announces Executive Changes Sep 09
New major risk - Revenue and earnings growth Aug 17
Second quarter 2023 earnings released: US$0.001 loss per share (vs US$0.01 loss in 2Q 2022) Aug 17
New minor risk - Shareholder dilution Jul 26
High number of new and inexperienced directors Jul 21
BioNexus Gene Lab Corporation has filed an IPO in the amount of $17.25 million. Feb 16 Bionexus Gene Lab Corporation Announces Management Changes BioNexus Gene Lab Corporation announced delayed annual 10-K filing Apr 03
BioNexus Gene Lab Corporation announced delayed 10-Q filing May 18
BioNexus Gene Lab Corporation (OTCPK:BGLC) agreed to acquire Chemrex Corporation Sdn. Bhd. Jan 01
Geschäftsführer Mr. Su-Leng Tan, also known as Lee, is CEO & Director of BioNexus Gene Lab Corp. from December 11, 2023 and also serves as its Acting Chief Financial Officer and Secretary. Mr. Tan was Chief Operating Offi ... Show more
Vorstandsmitglieder Name Position Amtszeit Vergütung Eigentümerschaft CEO, Acting CFO less than a year US$16.00k keine Daten Independent Non-Executive Director 2.7yrs US$3.00k keine Daten Independent Director less than a year keine Daten keine Daten
Mehr anzeigen 0.9yrs
Durchschnittliche Betriebszugehörigkeit 48yo
Durchschnittliches Alter
Erfahrener Vorstand: BGLCDie Vorstand smitglieder gelten nicht als erfahren ( 0.9 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
